|
|
||||||||
Original Research Communication |
1 From the Department of Nutritional Sciences (SRC, SLF, and CJL-K) and the Biobehavioral Sciences Graduate Program (EBT and HEM-D), the University of Connecticut, Storrs.
2 Represents Scientific Contribution no. 1965, Storrs Agricultural Experiment Station, University of Connecticut, Storrs.
3 Supported by grants from the NIH (HD 32903), the US Department of Agriculture (93-37200-8876), the Donaghue Medical Research Foundation, and the University of Connecticut Research Foundation.
4 Address reprint requests to CJ Lammi-Keefe, Department of Nutritional Sciences, University of Connecticut, U-17, 3624 Horsebarn Road Extension, Storrs, CT 06269-4017. E-mail: clammi{at}canr.uconn.edu.
| ABSTRACT |
|---|
|
|
|---|
Objective: We investigated whether CNS integrity in newborns, measured with sleep recordings, was associated with maternal concentrations of long-chain polyunsaturated fatty acids, especially DHA.
Design: Plasma phospholipid fatty acid concentrations were measured in 17 women at parturition. On postpartum day 1 (P1) and day 2 (P2), a pressure-sensitive pad under the infants bedding recorded body movements and respiratory patterns to measure sleep and wake states.
Results: Maternal plasma phospholipid DHA ranged from 1.91% to 4.5% by wt of total fatty acids. On the basis of previously published data and the median DHA concentration, the women were divided into 2 groups: high DHA (> 3.0% by wt of total fatty acids) and low DHA (
3.0% by wt of total fatty acids). Infants of high-DHA mothers had a significantly lower ratio of active sleep (AS) to quiet sleep (QS) and less AS than did infants of low-DHA mothers. Furthermore, the former infants had less sleep-wake transition and more wakefulness on P2. Correlations of maternal DHA status with infant sleep states were consistent with these data. Also, the ratio of maternal n-6 to n-3 fatty acids on P1 was inversely associated with QS and positively associated with arousals in QS. On P2, maternal n-6:n-3 was positively associated with AS, sleep-wake transition, and AS:QS.
Conclusion: The sleep patterns of infants born to mothers with higher plasma phospholipid DHA suggest greater CNS maturity.
Key Words: Long-chain polyunsaturated fatty acids long-chain PUFAs docosahexaenoic acid central nervous system infant sleep sleep recordings active sleep quiet sleep pregnancy prenatal nutrition maternal diet phospholipids
| INTRODUCTION |
|---|
|
|
|---|
The effects of LCPUFAs on visual development are well documented. Several studies showed that higher intakes of LCPUFAs, especially DHA, are associated with enhanced visual development (6, 7). Regarding brain development, suboptimal LCPUFA accretion into the developing central nervous system (CNS) is considered detrimental, because it might affect the childs emotional and intellectual development (8). However, the effect of fetal DHA status on the developing brain has not been investigated because of the lack of an appropriate assessment technique for use in the neonate. Because the developing nervous system is susceptible to potentially damaging factors of a biochemical or mechanical nature, any assessment technique must focus upon the functional integrity of the developing CNS (9). Measurements of the sleep and wake states of infants provide a tool for assessing the functional integrity of the CNS from the time of birth.
Infants sleep patterns are an expression of central integrative control (10). Multiple mechanisms involving both neural and humoral processes in various regions of the brain interact to produce sleep and wakefulness (11). Studies of the relation between sleep-state organization and CNS function showed that changes in sleep architecture are associated with neurologic changes during development and that deviant sleep patterns are associated with neurologic deficits (12, 13).
In the present study, we tested the hypothesis that the integrity of the CNS in newborns, assessed with prolonged sleep recordings, would be associated with maternal LCPUFA status, especially DHA status.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
Blood sample collection
At delivery, maternal venous blood was collected into tubes containing EDTA. The plasma and erythrocytes were separated with centrifugation (700 x g at 4 °C for 10 min). The plasma was divided into aliquots and stored at -80 °C until analyzed for phospholipid fatty acids. Infant blood samples were not collected because previous studies in our laboratory showed positive associations between maternal PUFA and cord blood PUFA concentrations (14). Thus, maternal PUFA status reflects infant PUFA status. Data regarding mode of delivery, birth weight, head circumference, Apgar scores, and birth trauma were collected from the medical records.
Sleep recordings
The sleep recordings were obtained by using the Motility Monitoring System (MMS) throughout the infants stay in the hospital. The basic principle underlying these sleep recordings is that each sleep or wake state involves a unique pattern of motility produced by respiration and body movements. This concept has been validated by comparing MMS data with direct observations and electroencephalogram recordings (15, 16).
The MMS consists of a capacitance-type sensor pad (12 inches x 24 inches x 1/8 inch thick) which is connected to an amplifier leading to a small 24-h data recorder. The sensor pad is placed under the sheet or mattress pad in the infants crib. The amplifier and recorder are battery-driven and fit into a briefcase that is suspended on the crib. A single channel of analogue signals from the infants respiration and body movements is transmitted from the sensor pad to the amplifier and then digitized (at 10 samples/s) and stored in the data logger. The data are transferred to a computer in the laboratory for processing and analysis. This procedure does not require the presence of an observer and permits continuous recording of data. The crib remains fully mobile during data collection. This method is nonintrusive because the instrumentation is not in direct contact with the infants body.
Sample analysis: plasma phospholipid fatty acids
Plasma phospholipid fatty acid concentrations were analyzed with methods described previously (17). In brief, the total lipid was extracted from the maternal plasma by using a modified Folch procedure (18) with 2:1 (vol:vol) dichloromethane:methanol. Thin-layer chromatography was used to separate the phospholipids, which were methylated to form the fatty acid methyl esters. We used 17:0 as an internal standard to determine absolute concentrations in mg/L. Fatty acid methyl esters were separated via injection into a Hewlett-Packard 6890 gas chromatograph (Hewlett-Packard, Wilmington, DE) equipped with an Omegawax 250 capillary column (30 m x 250 mm x 25 µm; Supelco, Bellefonte, PA). Plasma phospholipid fatty acid methyl esters were identified by comparison with external standards and were expressed as both relative % by wt of total fatty acids and absolute concentrations (mg/L).
Analysis of sleep recordings
In the laboratory, the recorded data were entered into a computer and scored by using a pattern-recognition program. Each 30-s period of the recording was scored for the sleep states of quiet sleep (QS), active sleep (AS), sleep-wake transition, wakefulness, and time spent out of the crib.
The computer program that we used for scoring the sleep states from analogue signals was developed on the basis of a template-matching process that compares waveform signals directly. The data profile for each 30-s period in an infants record is compared with data profiles from waveform regions that were selected as prototypical for each of the sleep states. The 19 standard templates were chosen from recordings of several infants from other studies, and > 1 template was chosen for each state because waveforms are not homogeneous for any of the states. The templates represent the range of motility patterns that occur in a behavioral state category. Computer assignment of a state to each successive 30-s period in the record is performed by comparing the profile for that period with the profile for each of the state templates in the file. The period is assigned to the state category of the template that it matches most closely. After an infants record is scored in 30-s periods, it is smoothed by using the following rule: 6 successive periods of AS, QS, or wakefulness are required for a change of state; thus, when
5 periods of a different state occur, the ongoing state is not changed.
After the computer scoring of each record, the full 24 h of signals is printed out for visual editing. For each 24-h observation, the following measures are obtained: 1) time spent in the crib, 2) percentage of time spent in each of the sleep states (QS, AS, sleep-wake transition, and wakefulness), 3) ratio of AS to QS, 4) brief arousals in AS, and 5) brief arousals in QS. Each of these measures was obtained separately for each infant on postpartum day 1 (P1) and day 2 (P2).
In previous studies, we repeatedly showed measurement reliability and validity for each of the sleep measures obtained from MMS recordings. Reliability of measurement was shown for preterm and full-term infants during the first 6 mo of life (10, 12, 1922). Validity was shown by making comparisons across species and procedures, including behavioral observations and electroencephalograms (16, 19, 2325). Predictive validity of the sleep measures was found for newborns (26) and for infants during the early postnatal weeks (12, 23).
Statistical analyses
Simple linear regression analyses were used to describe the associations between maternal LCPUFA status and infant sleep measures, separately on P1 and P2. For maternal DHA concentrations, we divided the women into 2 categories: high DHA (> 3.0% by wt of total fatty acids; n = 10) and low DHA (
3.0% by wt of total fatty acids; n = 7). The cutoff between the 2 categories was chosen on the basis of our previously published data on plasma phospholipid fatty acids of pregnant women in the third trimester (17) and the median DHA concentration (% by wt of total fatty acids) for this study population. Students t tests were used to analyze for significant differences between the group means for the descriptive data (age, maternal education, length of gestation, infant birth weight, birth length, head circumference, and Apgar score). Analysis of variance (ANOVA) was used to compare the maternal fatty acid profiles of the 2 groups. Repeated-measures ANOVA was used to analyze for the main effects of group and day on the sleep measures, and group-by-day interactions. P < 0.05 was considered statistically significant for the main effects of group and day and P < 0.10 was considered significant for the interaction effect. Furthermore, ANOVA was used to compare individual sleep measures of the 2 groups separately on P1 and P2 for variables with significant group-by-day interactions in the repeated-measures ANOVA. We considered maternal age and maternal education to be possible confounding variables and therefore we used them as covariates in the ANOVAs for group differences in sleep measures. The statistical analyses were performed with SAS, version 6.09 (SAS Institute Inc, Cary, NC).
| RESULTS |
|---|
|
|
|---|
The following correlations were the most significant among all the statistically significant correlations for this population. On P2, maternal DHA concentration was negatively associated with AS (r = -0.49, P < 0.05), AS:QS (r = -0.55, P < 0.05), and sleep-wake transition (r = -0.49, P < 0.05) and positively associated with wakefulness (r = 0.51, P < 0.05) (Figure 1
). On P1, the ratio of n-6 to n-3 LCPUFAs in maternal plasma was negatively associated with QS (r = -0.47, P = 0.05) and positively associated with arousals in QS (r = 0.51, P < 0.05) (Figure 2
). On P2, the ratio of n-6 to n-3 LCPUFAs in maternal plasma was positively associated with AS (r = 0.53, P < 0.05), AS:QS (r = 0.63, P < 0.01), and sleep-wake transition (r = 0.52, P < 0.05) and negatively associated with wakefulness (r = -0.53, P < 0.05) (Figure 2
).
|
|
|
-linolenic acid (20:3n-6), osbond acid (22:5n-6), eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), DHA,
n-3 PUFAs, and
n-3 LCPUFAs. Also, women in the high-DHA group had a significantly lower ratio of total n-6 LCPUFAs to total n-3 LCPUFAs compared with the low-DHA group. Concentrations of mead acid (20:3n-9), the most unsaturated and elongated of the n-9 fatty acids, did not differ significantly between the high-DHA and low-DHA groups.
|
|
| DISCUSSION |
|---|
|
|
|---|
Animal studies of n-3 deficiencies, especially DHA deficits, have provided the basis for studying the effects of different amounts of DHA on the functional status of human infants (33). Most of the human studies have focused on the effects of different amounts of DHA in the infants diet (ie, breast milk containing LCPUFAs compared with formulas with and without LCPUFAs) on postnatal CNS development (34, 35). Lucas et al (35) showed that infant neurodevelopment is dependent on factors that are present in breast milk but not in formula. Although definitive evidence supporting the association is lacking, these factors include LCPUFAs, specifically DHA, which is recognized as necessary for maturation of the CNS (36). Because neuronal proliferation and synaptogenesis begin late in gestation and continue into postnatal life (37), it is crucial to study the factors that affect prenatal and postnatal brain development. The prenatal supply of DHA is one such factor and is mostly dependent on maternal DHA status (17).
Several studies suggest that intakes of essential fatty acids may modulate sleep (3840). Malikova et al (38) reported that changes in the ratio of n-3 to n-6 fatty acids in the diet of guinea pigs affected the total sleeping time. Fagioli et al (39) characterized the effects of long-term deficiency of essential fatty acids on sleep organization by studying children who were maintained on fat-free total parenteral nutrition for 26 mo. These children had reduced amounts of slow-wave sleep compared with children who received total parenteral nutrition with essential fatty acids. These results suggest that intakes of essential fatty acids may modulate sleep (39). Furthermore, it was observed that breast-fed infants had a more mature pattern of CNS development than did formula-fed infants. The breast-fed infants had less AS and longer periods of QS (40). Our findings are consistent with these findings.
In a study of premature infants, Thoman and Whitney (12) found significantly different, distinctive sleep patterns in 4 groups of infants: those who showed normal development and those with a minimal mental deficiency, a neurologic disorder, or physical dysfunction. None of these infants had been diagnosed with an abnormality at the time of the early sleep recordings. In another study, Freudigman and Thoman (13) reported that a newborns sleep characteristics were related to mental and motor development at 6 mo. Thus, sleep recordings in early infancy provide a uniquely sensitive indication of subtle prenatal compromise, which may not have any apparent effects until a later age.
The present study had limitations in that it was a correlational analysis with a descriptive, nonrandomized design. However, the results provide evidence that prenatal exposure to higher concentrations of DHA results in a more mature pattern of sleep and wake states. QS, as a percentage of total sleep, increases from the time of birth until it is predominant at 3 mo postterm and thereafter (41). It is well documented that the increase in QS with age is largely a function of maturation of the nervous system and is not environmental (42). Thus, in our study, the lower amounts of AS and the greater amounts of QS observed in the infants exposed prenatally to higher DHA concentrations suggest greater CNS maturity compared with the infants exposed to lower DHA concentrations. Furthermore, the lower AS:QS observed in the infants in the high-DHA group shows that their sleep organization soon after birth was approaching that of normal, older infants. Generally, consolidation of sleep increases with age, and therefore less sleep-wake transition and more wakefulness in the infants in the high-DHA group also reflects greater maturity.
In addition, the ratio of total n-6 to n-3 fatty acids significantly influenced the integrity of the CNS. Prenatal exposure to a higher ratio of n-6 LCPUFAs to n-3 LCPUFAs resulted in sleep patterns that were contrary to those seen with a lower ratio of n-6 LCPUFAs to n-3 LCPUFAs and higher DHA concentrations. The higher ratio of n-6 to n-3 fatty acids was associated with more AS, less QS, more sleep-wake transition, less wakefulness, and a higher AS:QS. Furthermore, there was a highly significant positive association between the ratio of n-6 to n-3 fatty acids and arousals in QS. Arousals in QS are defined as QS fragmentation and are associated with CNS vulnerability (13). Future studies should consider maternal nutrition, health, socioeconomic status, and other related factors as potential correlates of DHA status.
The marked differences between the sleep measures on P1 and P2 were expected on the basis of our previous studies (13, 26). Research has shown that the characteristic changes in sleep patterns over the first 2 d postpartum, as seen in this study, occur in several other species. These changes are not only found in human newborns but also in newborn rats and rabbits (24, 25).
In conclusion, our findings suggest that differences in the prenatal supply of LCPUFAs, especially DHA, may modify brain phospholipids and affect neural function. Furthermore, the MMS is a reliable instrument for studying the CNS maturity of an individual infant in relation to infant DHA status. To our knowledge, this is the first report documenting that maternal DHA status during pregnancy, which is significantly influenced by dietary DHA, is associated with CNS maturity of the infant at birth.
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J A Dunstan, K Simmer, G Dixon, and S L Prescott Cognitive assessment of children at age 21/2 years after maternal fish oil supplementation in pregnancy: a randomised controlled trial Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2008; 93(1): F45 - F50. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Makrides and R. A. Gibson Marine Oil Supplements for Pregnant Women: Good for Mum, Good for Baby? NeoReviews, April 1, 2007; 8(4): e152 - e158. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L Jensen Effects of n-3 fatty acids during pregnancy and lactation Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1452 - 1457S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Coti Bertrand, J. R. O'Kusky, and S. M. Innis Maternal Dietary (n-3) Fatty Acid Deficiency Alters Neurogenesis in the Embryonic Rat Brain J. Nutr., June 1, 2006; 136(6): 1570 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Ludington-Hoe, M. W. Johnson, K. Morgan, T. Lewis, J. Gutman, P. D. Wilson, and M. S. Scher Neurophysiologic Assessment of Neonatal Sleep Organization: Preliminary Results of a Randomized, Controlled Trial of Skin Contact With Preterm Infants Pediatrics, May 1, 2006; 117(5): e909 - e923. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C McCann and B. N Ames Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals Am. J. Clinical Nutrition, August 1, 2005; 82(2): 281 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Vavasour Nutritional Implications of Observed Neurobehavioral Disturbances and Reduced Gestation Length in Infants of Mothers Using Selective Serotonin Reuptake Inhibitors During Pregnancy Pediatrics, July 1, 2004; 114(1): 325 - 325. [Full Text] [PDF] |
||||
![]() |
H. S Hansen and S. F. Olsen Sleep patterns, docosahexaenoic acid, and gestational length Am. J. Clinical Nutrition, February 1, 2004; 79(2): 334 - 334. [Full Text] [PDF] |
||||
![]() |
C. J Lammi-Keefe and E. B Thoman Reply to HS Hansen and SF Olsen Am. J. Clinical Nutrition, February 1, 2004; 79(2): 334 - 335. [Full Text] |
||||
![]() |
R S C Horne, P M Parslow, D Ferens, A-M Watts, and T M Adamson Comparison of evoked arousability in breast and formula fed infants Arch. Dis. Child., January 1, 2004; 89(1): 22 - 25. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |